Acepodia, Inc. (TPEX:6976)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
13.60
+0.05 (0.37%)
Feb 11, 2026, 1:49 PM CST
Market Cap8.03B -22.0%
Revenue (ttm)301.00K -98.2%
Net Income-655.56M
EPS-1.14
Shares Out582.22M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume548,632
Average Volume660,233
Open13.65
Previous Close13.60
Day's Range13.40 - 14.00
52-Week Range13.40 - 25.00
Beta0.63
RSI38.12
Earnings DateMar 19, 2026

About Acepodia

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in Phase 1 clinical trial; ACE183 that is in phase 1 clinical trial. Acepodia Inc. has strategic clinical collaboration with Pfizer Inc. for the development of antibody-cell conjugation... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Shih-Chia Hsiao
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 6976
Full Company Profile

Financial Performance

In 2024, Acepodia's revenue was 427,000, a decrease of -97.43% compared to the previous year's 16.59 million. Losses were -496.75 million, -39.22% less than in 2023.

Financial Statements